Clinical Trial Update: Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Amgen's apremilast is being studied in a Phase 3 pediatric trial for active juvenile psoriatic arthritis. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Psoriatic Arthritis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Active Juvenile Psoriatic Arthritis | Phase 3 | Status: RECRUITING